The patented 30% Glabridin extract (Glycyrrhiza glabra L.) is now legally usable in food supplements and beverages based on milk, yoghurt, fruit or vegetables at doses of 120mg per day.
Kaneka Pharma Europe said in a tatement: “After the complex EFSA regulatory process, we are pleased that Glavonoid has received Novel Food status today. Weight management is a major topic these days and with visceral fat a main risk factor for the development of a metabolic syndrome, we see an extremely promising market here.”
Glavonoid gained US New Dietary Ingredient (NDI) status in 2005 and Food and Drug Administration Generally Rrecognized as Safe (GRAS) status in 2008.